应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01801 信达生物
交易中 07-03 13:22:54
38.500
+1.100
+2.94%
最高
38.750
最低
37.300
成交量
165.22万
今开
37.900
昨收
37.400
日振幅
3.88%
总市值
626.79亿
流通市值
626.79亿
总股本
16.28亿
成交额
6,326万
换手率
0.10%
流通股本
16.28亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
国君晨报0703|固收、信达生物、华菱钢铁、主动配置、批零社服
国泰君安证券研究 · 06:56
国君晨报0703|固收、信达生物、华菱钢铁、主动配置、批零社服
港股异动 | 信达生物(01801)涨超5% 玛仕度肽有望25H1获批 机构看好其未来放量
智通财经 · 07-02 10:16
港股异动 | 信达生物(01801)涨超5% 玛仕度肽有望25H1获批 机构看好其未来放量
“体重管理年”提振“减肥降糖药”概念!港股创新药ETF(159567)跟踪指数趋势上行,金斯瑞生物科技、信达生物、诺诚健华领涨。
有连云 · 07-02 10:01
“体重管理年”提振“减肥降糖药”概念!港股创新药ETF(159567)跟踪指数趋势上行,金斯瑞生物科技、信达生物、诺诚健华领涨。
南向资金6月28日净买入信达生物55.81万股 连续3日增持
自选股智能写手 · 07-02 09:31
南向资金6月28日净买入信达生物55.81万股 连续3日增持
信达生物在2024年欧洲肿瘤内科学会胃肠道肿瘤大会(ESMO GI)口头报告创新型抗CLDN18.2 ADC(IBI343)在晚期胃或胃食管交界处腺癌的最新研究数据
美通社 · 07-02 08:00
信达生物在2024年欧洲肿瘤内科学会胃肠道肿瘤大会(ESMO GI)口头报告创新型抗CLDN18.2 ADC(IBI343)在晚期胃或胃食管交界处腺癌的最新研究数据
国泰君安:信达生物(01801)玛仕度肽有望25H1获批 维持“增持”评级
智通财经 · 07-01 10:05
国泰君安:信达生物(01801)玛仕度肽有望25H1获批 维持“增持”评级
信达生物(01801)下跌5.12%,报37.05元/股
金融界 · 06-28
信达生物(01801)下跌5.12%,报37.05元/股
信达生物盘中异动 股价大跌5.12%报37.050港元
自选股智能写手 · 06-28
信达生物盘中异动 股价大跌5.12%报37.050港元
为生命,更添美好 | 信达生物综合管线临床数据最新解读分享
美通社 · 06-28
为生命,更添美好 | 信达生物综合管线临床数据最新解读分享
信达生物制药(苏州)有限公司药品申请临床试验默示许可获受理
金融界 · 06-27
信达生物制药(苏州)有限公司药品申请临床试验默示许可获受理
信达生物(01801)上涨4.48%,报39.65元/股
金融界 · 06-26
信达生物(01801)上涨4.48%,报39.65元/股
港股异动 | 信达生物(01801)现涨超3% 玛仕度肽展现积极效果 减重效果优于同类竞品
智通财经 · 06-26
港股异动 | 信达生物(01801)现涨超3% 玛仕度肽展现积极效果 减重效果优于同类竞品
信达生物玛仕度肽:年底获批上市,2025年销售预期7亿人民币
和讯网 · 06-26
信达生物玛仕度肽:年底获批上市,2025年销售预期7亿人民币
交银国际:维持信达生物(01801)“买入”评级 目标价48港元
智通财经 · 06-26
交银国际:维持信达生物(01801)“买入”评级 目标价48港元
信达生物(01801)出现大手卖出13.3万股,成交价$38.5,涉资512.05万
阿斯达克财经 · 06-26
信达生物(01801)出现大手卖出13.3万股,成交价$38.5,涉资512.05万
【券商聚焦】交银国际维持信达生物(01801)买入评级 指玛仕度肽减重效果优于同类竞品
金吾财讯 · 06-26
【券商聚焦】交银国际维持信达生物(01801)买入评级 指玛仕度肽减重效果优于同类竞品
信达生物减肥药mazdutide效果接近礼来Zepbound
金融界 · 06-26
信达生物减肥药mazdutide效果接近礼来Zepbound
信达生物/礼来减肥药玛仕度肽展现显著改善患者脂肪肝效果
金融界 · 06-25
信达生物/礼来减肥药玛仕度肽展现显著改善患者脂肪肝效果
智通港股解盘 | 对不利因素“脱敏” 财税体制改革或带来机遇
智通财经 · 06-25
智通港股解盘 | 对不利因素“脱敏” 财税体制改革或带来机遇
更新版 1-诺和诺德的司美格鲁肽在中国获准“名正言顺”用来减肥,A股概念股逆市上扬
Reuters · 06-25
更新版 1-诺和诺德的司美格鲁肽在中国获准“名正言顺”用来减肥,A股概念股逆市上扬
加载更多
公司概况
公司名称:
信达生物
所属市场:
SEHK
上市日期:
--
主营业务:
信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销,以及提供咨询及研发服务。该公司的主要产品为达伯舒(信迪利单抗注射液),用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303,用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305,用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌(NSCLC)。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。
发行价格:
--
{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":38.5,"timestamp":1719984142537,"preClose":37.4,"halted":0,"volume":1652231,"delay":0,"floatShares":1628022690,"shares":1628022690,"eps":-0.70440006,"marketStatus":"交易中","marketStatusCode":2,"change":1.1,"latestTime":"07-03 13:22:54","open":37.9,"high":38.75,"low":37.3,"amount":63263034,"amplitude":0.03877,"askPrice":38.5,"askSize":9500,"bidPrice":38.45,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.7053929511770175,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1719994200000},"adr":0,"listingDate":1540915200000,"adjPreClose":37.4,"openAndCloseTimeList":[[1719970200000,1719979200000],[1719982800000,1719993600000]],"volumeRatio":0.513173,"impliedVol":0.5323,"impliedVolPercentile":0.246,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK"},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2448011295","title":"国君晨报0703|固收、信达生物、华菱钢铁、主动配置、批零社服","url":"https://stock-news.laohu8.com/highlight/detail?id=2448011295","media":"国泰君安证券研究","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448011295?lang=zh_cn&edition=full","pubTime":"2024-07-03 06:56","pubTimestamp":1719960960,"startTime":"0","endTime":"0","summary":"制造业PMI反映的现状依然是需求向下拖累生产、价格回升的趋势还需确认、经济动能有待进一步提升。玛仕度肽减重效果优异,肝脏脂肪减少超80%,有望进入MASH治疗市场。在CLDN18.2表达量≥60%患者中,ORR为38.5%。在PD-L1阳性患者中,ORR为30.8%。2024Q1营收370.48亿元,同比降7.13%;归母净利润3.92亿元,同比降43.13%,业绩略不及预期。不利因素逐步消退,2024Q2业绩有望回升。2023年公司重点品种钢销量1683万吨,占比63%,环比再升3个百分点,较2016年已累计升31个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650481161&idx=2&sn=4e224da43d80a22f558ab81f6022250d&chksm=89b26e2434ba97ad7a75cb25bf799506087290d538da3a8a035f21229f599f32b6ddef3fd149&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU2328871848.SGD","BK1583","LU1969619763.USD","01801","BK1161","BK1589"],"gpt_icon":0},{"id":"2448974182","title":"港股异动 | 信达生物(01801)涨超5% 玛仕度肽有望25H1获批 机构看好其未来放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2448974182","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448974182?lang=zh_cn&edition=full","pubTime":"2024-07-02 10:16","pubTimestamp":1719886619,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,信达生物涨超5%,截至发稿,涨5.03%,报38.50港元,成交额7620.54港元。国泰君安发布研究报告称,信达生物综合管线和肿瘤管线临床数据密集读出,PD-1/IL2、CLND18.2ADC、CLDN18.2/CD3临床数据优异,玛仕度肽有望25H1获批,市场潜力巨大,维持“增持”评级。近期诺和诺德表示,为了保证全球药物供应,将限制Wegovy(减重)中国地区销售,玛仕度肽有望25H1获批上市,竞争格局良好,看好其未来放量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSCEI","07226","YANG","01801","BK1583","LU1969619763.USD","BK1589","BK1161","HSTECH","LU2328871848.SGD"],"gpt_icon":0},{"id":"2448971514","title":"“体重管理年”提振“减肥降糖药”概念!港股创新药ETF(159567)跟踪指数趋势上行,金斯瑞生物科技、信达生物、诺诚健华领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2448971514","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448971514?lang=zh_cn&edition=full","pubTime":"2024-07-02 10:01","pubTimestamp":1719885719,"startTime":"0","endTime":"0","summary":"2024年7月2日,港股创新药板块开盘走强。盘面上,金斯瑞生物科技领涨,信达生物、诺诚健华跟涨,港股创新药ETF市场热度较高,过去5个交易日日均成交额5505万元。首创证券表示,2024年6月26日,国家卫生健康委等16个部门联合制定并发布《“体重管理年”活动实施方案》。本次活动方案有助于提升社会大众对于减重在健康管理中重要性的认知,减重药物需求有望进入快速增长阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070210020195630781&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070210020195630781&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1589","LU2328871848.SGD","BK1161","09969","01548","BK1574","01801","688428","BK1583","LU1969619763.USD","BK1141"],"gpt_icon":0},{"id":"2448795419","title":"南向资金6月28日净买入信达生物55.81万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2448795419","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448795419?lang=zh_cn&edition=full","pubTime":"2024-07-02 09:31","pubTimestamp":1719883893,"startTime":"0","endTime":"0","summary":"6月28日, 南向资金增持信达生物55.81万股,连续3日增持。截止当日收盘,港股通共持有信达生物32207.22万股,占流通股19.77%。港股通增持金额前五个股分别为工商银行、建设银行、中国石油化工股份、招商银行、兖矿能源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407020941199562e54c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407020941199562e54c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU2328871848.SGD","01801","BK1583","BK1589","BK1161"],"gpt_icon":0},{"id":"2448920579","title":"信达生物在2024年欧洲肿瘤内科学会胃肠道肿瘤大会(ESMO GI)口头报告创新型抗CLDN18.2 ADC(IBI343)在晚期胃或胃食管交界处腺癌的最新研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2448920579","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448920579?lang=zh_cn&edition=full","pubTime":"2024-07-02 08:00","pubTimestamp":1719878400,"startTime":"0","endTime":"0","summary":"\" 除胃癌外,IBI343还在胰腺癌等实体瘤上探索治疗潜力。CLDN18.2 在胃癌患者中表达率达 80%。作为创新型TOPO1i型ADC,IBI343在临床I期研究中展现出可控的安全性和令人鼓舞的疗效性信号,目前正在胃癌和胰腺癌等瘤种上探索IBI343的治疗潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4452317_ZH52317_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","LU2328871848.SGD","IVBIY","01801","ADC","BK4080","BK1583","LU1969619763.USD","BK1589","BK1161","BK4231"],"gpt_icon":0},{"id":"2448939388","title":"国泰君安:信达生物(01801)玛仕度肽有望25H1获批 维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2448939388","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448939388?lang=zh_cn&edition=full","pubTime":"2024-07-01 10:05","pubTimestamp":1719799523,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,国泰君安发布研究报告称,信达生物综合管线和肿瘤管线临床数据密集读出,PD-1/IL2、CLND18.2ADC、CLDN18.2/CD3临床数据优异,玛仕度肽有望25H1获批,市场潜力巨大,维持“增持”评级。国泰君安主要观点如下:玛仕度肽减重效果优异,肝脏脂肪减少超80%,有望进入MASH治疗市场。近期诺和诺德表示,为了保证全球药物供应,将限制Wegovy(减重)中国地区销售,玛仕度肽有望25H1获批上市,竞争格局良好,看好其未来放量。在PD-L1阳性患者中,ORR为30.8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02611","01801"],"gpt_icon":0},{"id":"2446528827","title":"信达生物(01801)下跌5.12%,报37.05元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446528827","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446528827?lang=zh_cn&edition=full","pubTime":"2024-06-28 13:58","pubTimestamp":1719554329,"startTime":"0","endTime":"0","summary":"6月28日,信达生物(01801)盘中下跌5.12%,截至13:58,报37.05元/股,成交1.6亿元。信达生物制药主营业务是开发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物,已成功建立起了包括35个新药品种的产品链,并获得9个产品的批准上市。至2023年3月,信达生物的患者援助项目已惠及16余万普通患者,药物捐赠总价值数亿元,与礼来、罗氏、赛诺菲等公司达成了30项战略合作。截至2023年年报,信达生物营业总收入62.06亿元、净利润-10.28亿元。6月26日,浦银国际证券维持买入评级,目标价60港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/28135841256151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01801","BK1583","LU2328871848.SGD","BK1589","LU1969619763.USD"],"gpt_icon":0},{"id":"2446528843","title":"信达生物盘中异动 股价大跌5.12%报37.050港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446528843","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446528843?lang=zh_cn&edition=full","pubTime":"2024-06-28 13:58","pubTimestamp":1719554322,"startTime":"0","endTime":"0","summary":"2024年06月28日下午盘13时58分,信达生物股票出现波动,股价大幅下挫5.12%。截至发稿,该股报37.050港元/股,成交量418.322万股,换手率0.26%,振幅5.63%。资金方面,该股资金流入5159.84万港元,流出7989.01万港元。信达生物股票所在的药品行业中,整体跌幅为0.13%。该公司的产品还包括阿达木单抗生物类似药IBI-303,用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240628135842941f225d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240628135842941f225d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","LU1969619763.USD","LU2328871848.SGD","BK1589","01801"],"gpt_icon":0},{"id":"2446901405","title":"为生命,更添美好 | 信达生物综合管线临床数据最新解读分享","url":"https://stock-news.laohu8.com/highlight/detail?id=2446901405","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446901405?lang=zh_cn&edition=full","pubTime":"2024-06-28 08:00","pubTimestamp":1719532800,"startTime":"0","endTime":"0","summary":"6月25日,信达生物召开投资者电话会,详细解读玛仕度肽临床数据。信达生物首席财务官由飞女士、综合管线临床开发副总裁钱镭博士参加会议并进行汇报。经过48周的治疗,玛仕度肽6mg剂量组和基线对比相较安慰剂平均体重下降了14.3%,这一数据极具竞争力。代谢类疾病高度影响老百姓的生活质量和幸福指数,信达生物将在该领域加速创新,致力于解决未满足的临床需求,为患者带来更安全、更有效的治疗方案。信达生物在不断开发创新药物、谋求","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4450207_ZH50207_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4017","BK4139","CVM","SLE","BK1161","BK4077","CDE","01801","IVBIY","BK1583","LU2328871848.SGD","BK1589","LU1969619763.USD"],"gpt_icon":0},{"id":"2446308772","title":"信达生物制药(苏州)有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2446308772","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446308772?lang=zh_cn&edition=full","pubTime":"2024-06-27 13:56","pubTimestamp":1719467794,"startTime":"0","endTime":"0","summary":"6月27日,据CDE官网消息,信达生物制药(苏州)有限公司联合申请药品“信迪利单抗注射液”,获得临床试验默示许可,受理号CXSL2400251。公示信息显示,药品“信迪利单抗注射液”适应症:本品联合IBI310用于可切除的高微卫星不稳定性(MSI-H)或错配修复基因缺陷型(dMMR)结肠癌患者的新辅助治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062714021995dd047a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062714021995dd047a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","01801","BK1161","BK1191","BK1574","BK1141","01477","03347","LU2328871848.SGD","BK1576","BK1589","BK1583"],"gpt_icon":0},{"id":"2446811358","title":"信达生物(01801)上涨4.48%,报39.65元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446811358","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446811358?lang=zh_cn&edition=full","pubTime":"2024-06-26 15:33","pubTimestamp":1719387206,"startTime":"0","endTime":"0","summary":"6月26日,信达生物(01801)盘中上涨4.48%,截至15:33,报39.65元/股,成交3.03亿元。信达生物制药主营业务是开发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物,已成功建立起了包括35个新药品种的产品链,并获得9个产品的批准上市。至2023年3月,信达生物的患者援助项目已惠及16余万普通患者,药物捐赠总价值数亿元,与礼来、罗氏、赛诺菲等公司达成了30项战略合作。截至2023年年报,信达生物营业总收入62.06亿元、净利润-10.28亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/26153341209965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2328871848.SGD","LU1969619763.USD","BK1161","BK1589","BK1583","01801"],"gpt_icon":0},{"id":"2446331759","title":"港股异动 | 信达生物(01801)现涨超3% 玛仕度肽展现积极效果 减重效果优于同类竞品","url":"https://stock-news.laohu8.com/highlight/detail?id=2446331759","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446331759?lang=zh_cn&edition=full","pubTime":"2024-06-26 14:31","pubTimestamp":1719383516,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,信达生物现涨超3%,截至发稿,涨3.29%,报39.2港元,成交额2.43亿港元。消息面上,信达生物与礼来共同开发的GLP-1R/GCGR双重激动剂玛仕度肽展现减肥+显著改善脂肪肝的效果。交银国际发研报指,信达生物玛仕度肽减重效果优于同类竞品。未来12个月重点关注玛仕度肽、ROS1、KRAS等新品获批后的初始销售,以及IL2、CLDN18.2后续数据更新。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU1969619763.USD","LU2328871848.SGD","BK1589","01801","BK1161","07226","HSTECH","YANG","HSCEI"],"gpt_icon":0},{"id":"2446313083","title":"信达生物玛仕度肽:年底获批上市,2025年销售预期7亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2446313083","media":"和讯网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446313083?lang=zh_cn&edition=full","pubTime":"2024-06-26 11:15","pubTimestamp":1719371745,"startTime":"0","endTime":"0","summary":"快讯正文信达生物的玛仕度肽有望在年底前在中国获得上市批准,预计2025年和2026年的销售额将分别达到7亿和18亿元人民币,峰值销售预测为52亿元。交银国际维持对信达生物的“买入”评级,目标价设定为48港元。玛仕度肽的减重效果显著,6mg组在48周内减重14.0%至14.8%,远超安慰剂组。信达生物正考虑将玛仕度肽的应用扩展至青少年肥胖、心衰、睡眠呼吸暂停等领域,这些领域存在巨大的未满足临床需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062614172795d91f6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062614172795d91f6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","LU2328871848.SGD","BK1589","LU1969619763.USD","BK1161","BK1583"],"gpt_icon":0},{"id":"2446078383","title":"交银国际:维持信达生物(01801)“买入”评级 目标价48港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446078383","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446078383?lang=zh_cn&edition=full","pubTime":"2024-06-26 10:08","pubTimestamp":1719367684,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,交银国际发布研究报告称,维持信达生物“买入”评级,目标价48港元。未来12个月重点关注玛仕度肽、ROS1、KRAS等新品获批后的初始销售,以及IL2、CLDN18.2后续数据更新。交银国际主要观点如下:玛仕度肽减重效果优于同类竞品:在疗法估计目标和疗效估计目标下,玛仕度肽6mg组在48周分别减重14.0%/14.8%,相较安慰剂组的差异达到14.3%/14.4%。该行预计玛仕度肽将于年底前后在中国获批上市,2025/26年/峰值销售分别达到7亿/18亿/52亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801"],"gpt_icon":0},{"id":"2446800364","title":"信达生物(01801)出现大手卖出13.3万股,成交价$38.5,涉资512.05万","url":"https://stock-news.laohu8.com/highlight/detail?id=2446800364","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446800364?lang=zh_cn&edition=full","pubTime":"2024-06-26 09:20","pubTimestamp":1719364800,"startTime":"0","endTime":"0","summary":"[大手成交]信达生物(01801)在上午09:20出现大手卖出,成交量为13.3万,成交价为港币$38.5,涉资512.05万。至目前为止,股价升1.449%,今日最高价为$38.5,而最低价为$38.5,总成交量为17.65万股,总成交金额港币$677.132万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT24062618/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","LU1969619763.USD","01801","BK1161","BK1589","LU2328871848.SGD"],"gpt_icon":0},{"id":"2446802858","title":"【券商聚焦】交银国际维持信达生物(01801)买入评级 指玛仕度肽减重效果优于同类竞品","url":"https://stock-news.laohu8.com/highlight/detail?id=2446802858","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446802858?lang=zh_cn&edition=full","pubTime":"2024-06-26 09:05","pubTimestamp":1719363922,"startTime":"0","endTime":"0","summary":"在疗法估计目标和疗效估计目标下,玛仕度肽6mg组在48周分别减重14.0%/14.8%,相较安慰剂组的差异达到14.3%/14.4%。相比同靶点竞品,玛仕度肽6mg的减重数据优于司美格鲁肽2.4mg和替尔泊肽10mg。该行维持买入评级和48.0港元的目标价。未来12个月重点关注玛仕度肽、ROS1、KRAS等新品获批后的初始销售,以及IL2、CLDN18.2后续数据更新。","market":"other","thumbnail":"https://static.szfiu.com/news/20200908/MTI0OTYzODIzODM=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MTI0OTYzODIzODM=.png"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1939291","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"gpt_icon":0},{"id":"2446803893","title":"信达生物减肥药mazdutide效果接近礼来Zepbound","url":"https://stock-news.laohu8.com/highlight/detail?id=2446803893","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446803893?lang=zh_cn&edition=full","pubTime":"2024-06-26 07:05","pubTimestamp":1719356708,"startTime":"0","endTime":"0","summary":"信达生物联合礼来制药开发一款减肥药mazdutide,后期临床试验结果证明,持续48周采用该药品更高剂量的受试对象减重将近15%,试验中有4mg、6mg、或者安慰剂三种选项。与此同时,采用更高剂量药品后,肝脏脂肪减少80%。Bloomberg Intelligence分析师Michael Shah和Leslie Yang表示,试验结果表明,信达生物的减肥效果极大程度上与礼来Zepbound减轻体重的磅数相当。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406260707479f65694e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406260707479f65694e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LLY","LU2237443549.SGD","LU1623119135.USD","LU2265009873.SGD","IE00BJJMRZ35.SGD","LU0708995401.HKD","LU0882574139.USD","LU2491049909.HKD","LU1551013342.USD","LU1712237335.SGD","BK4533","LU0256863811.USD","LU0820561818.USD","LU0097036916.USD","IE0002141913.USD","LU1551013425.SGD","LU2264538146.SGD","LU1280957306.USD","IE0009355771.USD","BK4534","IE0004445239.USD","LU0061475181.USD","LU0114720955.EUR","LU0058720904.USD","LU0109391861.USD","LU1988902786.USD","LU2237443978.SGD","LU2237443382.USD","LU1057294990.SGD","IE00BFTCPJ56.SGD","LU1814569148.SGD","LU0079474960.USD","01801","GB00BDT5M118.USD","LU2468319806.SGD","BK4007","LU0820561909.HKD","LU2237438978.USD","IE00B1BXHZ80.USD","LU0289739699.SGD","LU0882574055.USD","LU0122379950.USD","LU0943347566.SGD","LU2237443622.USD","LU1023059063.AUD","LU2491050071.SGD","LU0385154629.USD","LU1804176565.USD","LU0689472784.USD","IE00BJT1NW94.SGD","LU0466842654.USD"],"gpt_icon":0},{"id":"2446884153","title":"信达生物/礼来减肥药玛仕度肽展现显著改善患者脂肪肝效果","url":"https://stock-news.laohu8.com/highlight/detail?id=2446884153","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446884153?lang=zh_cn&edition=full","pubTime":"2024-06-25 21:32","pubTimestamp":1719322363,"startTime":"0","endTime":"0","summary":"在一项中国Ⅲ期实验中,中国信达生物制药与美国礼来公司共同开发的新减肥药展现出受试者体重显著降低,同时肝脂肪含量显著下降的效果。根据公告,GLP-1R/GCGR双重激动剂玛仕度肽在中国超重或肥胖成人受试者的首个III期临床研究(GLORY-1)中,高剂量组的受试者在48周内减轻了15%的体重,同时在基线肝脂肪含量≥10%的受试者中,经过48周6mg玛仕度肽治疗后,患者肝脂肪含量较基线平均降幅达80.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406252145359f6416d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406252145359f6416d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1589","01801","LU1969619763.USD","LU2328871848.SGD","LLY"],"gpt_icon":0},{"id":"2446323849","title":"智通港股解盘 | 对不利因素“脱敏” 财税体制改革或带来机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2446323849","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446323849?lang=zh_cn&edition=full","pubTime":"2024-06-25 21:20","pubTimestamp":1719321624,"startTime":"0","endTime":"0","summary":"当地时间6月23日,克里米亚塞瓦斯托波尔市遭遇乌克兰导弹袭击。当地时间24日,俄罗斯直接指责美国,称乌克兰在此次袭击中使用了美国提供的ATACMS导弹,并威胁“势必回击”。诡异的是,有些网友表示他们并未在OpenAI罗列的不支持的国家和地区使用,却依然遭到了使用限制或封禁。本次吸收合并交易的现金对价港币24.6元/股,对复宏汉霖H股不受干扰日收盘价的溢价为36.67%,现金对价合计不超过约54.07亿港元或等值人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00268","LU0456827905.SGD","BK1171","LU0051755006.USD","LU1969619763.USD","82333","BK1607","BK1119","BK1522","BK1539","YANG","00127","07226","BK1526","BK1517","HSCEI","01801","GWLLY","BK1601","HSTECH","SG9999014674.SGD","02696","02333","BK1216","BK1589","601633","IE0034224299.USD","BK1161","BK1583","LU2328871848.SGD","BK1518","BK1109","02338","BK1586","SG9999006597.SGD"],"gpt_icon":0},{"id":"2446471897","title":"更新版 1-诺和诺德的司美格鲁肽在中国获准“名正言顺”用来减肥,A股概念股逆市上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=2446471897","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446471897?lang=zh_cn&edition=full","pubTime":"2024-06-25 17:39","pubTimestamp":1719308396,"startTime":"0","endTime":"0","summary":" 路透上海6月25日 - 丹麦诺和诺德 的司美格鲁肽号称“减肥神药”,在爱美人士中走红。现在这款药物终于在中国原研专利到期前,被批准用于治疗超重和肥胖症。这意味着中国也成为继日本之后,第二个批准诺和诺德的司美格鲁肽治疗肥胖的亚洲国家。诺和诺德大中国区高管在3月表示,在中国推出的用于减肥的司美格鲁肽最开始将以自费患者为主。诺和诺德的司美格鲁肽在中国的专利将于2026年3月20日到期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU0672654240.SGD","LU1814569148.SGD","IE00BJT1NW94.SGD","BK4533","LU1551013425.SGD","BK0183","LU0417517546.SGD","IE0002141913.USD","BK0175","LU2491049909.HKD","03692","LU0079474960.USD","LU2237438978.USD","399300","LU0058720904.USD","159982","LU1988902786.USD","GB00BDT5M118.USD","000963","LU2491050071.SGD","LU2264538146.SGD","BK1589","BK4007","LU1023059063.AUD","LU2468319806.SGD","LU0256863811.USD","LLY","LU0289739699.SGD","LU0882574055.USD","IE00B1BXHZ80.USD","LU1804176565.USD","LU2148510915.USD","LU1057294990.SGD","BK0070","IE0004445239.USD","300199","01801","300122","LU0708995401.HKD","LU1064130708.USD","BK0239","BK4534","LU1280957306.USD","BK1161","BK0077","LU0122379950.USD","LU0109391861.USD","LU1551013342.USD","LU0061475181.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0145},{"period":"1month","weight":0.0625},{"period":"3month","weight":0.0346},{"period":"6month","weight":-0.101},{"period":"1year","weight":0.2467},{"period":"ytd","weight":-0.1251}],"compareEarnings":[{"period":"1week","weight":-0.0168},{"period":"1month","weight":-0.0172},{"period":"3month","weight":0.0624},{"period":"6month","weight":0.0675},{"period":"1year","weight":-0.0796},{"period":"ytd","weight":0.0423}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销,以及提供咨询及研发服务。该公司的主要产品为达伯舒(信迪利单抗注射液),用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303,用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305,用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌(NSCLC)。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.049204},{"month":2,"riseRate":0.666667,"avgChangeRate":0.101831},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.050735},{"month":4,"riseRate":0.666667,"avgChangeRate":0.022046},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006538},{"month":6,"riseRate":0.666667,"avgChangeRate":0.118103},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.035823},{"month":8,"riseRate":0.8,"avgChangeRate":-0.016733},{"month":9,"riseRate":0.6,"avgChangeRate":0.024076},{"month":10,"riseRate":0.4,"avgChangeRate":0.043974},{"month":11,"riseRate":0.5,"avgChangeRate":0.068539},{"month":12,"riseRate":0.5,"avgChangeRate":0.07208}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}